Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    

ALLERGAN, INC.
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 03:54pm CEST

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
2017Mylan defends chairman to ISS ahead of June 22 investor vote
RE
2017ALLERGAN : to Present New Data on Chronic Migraine at the American Headache Soci..
PU
2017FEATURED COMPANY NEWS - MYLAN LAUNCH : Generic Reclast® Injection and Generic Az..
AQ
2017U.S. state, local government lawsuits over opioids face uphill battle
RE
2017ALLERGAN : to Present Data from its Anti-Infectives Portfolio at ASM Microbe 201..
PU
2017ALLERGAN PLC : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
2017ALLERGAN PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2017ALLERGAN : Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch R..
PU
2017ALLERGAN PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2017HEALTH CANADA APPROVES ALLERGAN PLC : AGN) IBS Drug Viberzi
AQ
More news
News from SeekingAlpha
2015MANNKIND : A Head Pain Gain Or A Pocket-Book Drain? 
2015Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update 
2015Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update 
2015Time Warner Is A Buy - Cramer's Lightning Round (5/21/15) 
2015Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update 
Chart ALLERGAN, INC.
Duration : Period :
Allergan, Inc. Technical Analysis Chart | US0184901025 | 4-Traders
Managers
NameTitle
Ambrose Robert Douglas Bailey Chief Executive Officer
Maria Teresa Hilado Chief Financial Officer
Raymond H. Diradoorian Executive VP-Global Technical Operations
Joann Bradley Investor Relations Contact
David Nakasone Investor Relations Contact
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.0
JOHNSON & JOHNSON-9.68%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.66%193 904
MERCK AND COMPANY5.97%161 967